Article
Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Journal of psychopharmacology (Oxford, England) - 1 Mar 2012
Cho Soo-Churl, Kim Bung-Nyun, Cummins Tarrant D R, Kim Jae-Won, Bellgrove Mark A
Abstract excerpt
The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7 ± 1.7 years) were recruited from child psychiatric centers at six university hospitals...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
